

18.	Segment Data

During the first quarter of fiscal 2015, the integration of Questcor was substantially completed. With this, and given the increased significance of the Specialty Brands business to the Company's results and the expected long-term growth of this business as compared to the Specialty Generics business, the Company changed its reportable segments during the first quarter. The Company now presents the Specialty Brands and Specialty Generics businesses as reportable segments, along with the continued presentation of Global Medical Imaging as a reportable segment. The Company historically presented the Specialty Brands and Specialty Generics businesses within the Specialty Pharmaceuticals segment. Prior year amounts have been recast to conform to current presentation. The three reportable segments are further described below:


•	Specialty Brands produces and markets branded pharmaceuticals and biopharmaceuticals;


•	Specialty Generics produces specialty generic pharmaceuticals and API consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients; and


•	Global Medical Imaging manufactures and markets CMDS and radiopharmaceuticals (nuclear medicine).

Selected information by business segment was as follows:



	Three Months Ended						Nine Months Ended
	June 26, 2015			June 27, 2014			June 26, 2015			June 27, 2014
Net sales:
Specialty Brands	$	446.2		$	84.9		$	1,154.1		$	199.6
Specialty Generics	307.9			329.4			954.9			848.5
Global Medical Imaging	201.6			227.1			603.5			668.1
Net sales of operating segments ⁽¹⁾	955.7			641.4			2,712.5			1,716.2
Other ⁽²⁾	9.4			11.7			28.8			34.9
Net sales	$	965.1		$	653.1		$	2,741.3		$	1,751.1
Operating income:
Specialty Brands	$	189.2		$	(51.4	)	$	434.8		$	(85.8	)
Specialty Generics	157.2			177.0			501.4			430.3
Global Medical Imaging	34.6			11.2			77.1			25.9
Segment operating income	381.0			136.8			1,013.3			370.4
Unallocated amounts:
Corporate and allocated expenses ⁽³⁾	(74.7		)	(63.6		)	(224.2		)	(161.5		)
Intangible asset amortization	(149.6		)	(51.6		)	(398.7		)	(75.9		)
Restructuring and related charges, net ⁽⁴⁾	(23.1		)	(24.2		)	(34.2		)	(54.0		)
Separation costs	—			(1.8		)	—			(6.6		)
Operating income	$	133.6		$	(4.4	)	$	356.2		$	72.4


(1)	Amounts represent sales to external customers.


(2)	Represents products that were sold to the Company's former parent company, which is discussed in Note 14.


(3)	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.


(4)	Includes restructuring-related accelerated depreciation of $0.4 million for the three months ended June 27, 2014, and $0.2 million and $0.5 million for the nine months ended June 26, 2015 and June 27, 2014, respectively.

Net sales by product family within the Company's segments are as follows:



	Three Months Ended				Nine Months Ended
	June 26, 2015		June 27, 2014		June 26, 2015		June 27, 2014
Acthar	$	268.7	$	—	$	763.1	$	—
Ofirmev	62.1		53.2		201.6		58.5
Inomax	81.5		—		81.5		—
EXALGO®	8.6		8.6		32.7		73.7
Other	25.3		23.1		75.2		67.4
Specialty Brands	$	446.2	$	84.9	$	1,154.1	$	199.6

Oxycodone (API) and oxycodone-containing tablets	$	31.6	$	53.8	$	127.2	$	101.7
Hydrocodone (API) and hydrocodone-containing tablets	37.4		25.3		138.0		75.1
Methylphenidate ER	30.0		54.7		112.6		154.3
Other controlled substances	157.4		154.4		414.7		408.6
Other	51.5		41.2		162.4		108.8
Specialty Generics	$	307.9	$	329.4	$	954.9	$	848.5

Optiray™	$	58.5	$	76.0	$	177.5	$	219.4
Other	34.3		40.7		105.8		121.5
Contrast Media and Delivery Systems	92.8		116.7		283.3		340.9
Nuclear Imaging	108.8		110.4		320.2		327.2
Global Medical Imaging	$	201.6	$	227.1	$	603.5	$	668.1